Back
HCV Treatment 
Drug Advisories & Warnings
Drug Advisories & Warnings
Complera Label Adds Low Viral Load Restriction, Liver Toxicity Warning
- Details
- Category: HIV Treatment
- Published on Tuesday, 29 January 2013 00:00
- Written by FDA
The U.S. Food and Drug Administration (FDA) last week approved revised label information for Complera, Gilead Sciences' tenofovir/emtricitabine/rilpivirine single-tablet regimen. Among the changes, the updated label clarifies that this regimen is indicated for previously untreated people with low baseline viral load, as those with higher levels were more likely to experience treatment failure in clinical trials.
More Articles...
- Kaletra Label Updated to Add Drug Interactions, Including Boceprevir and Telaprevir
- Telaprevir Label Gets Black Box Warning about Serious Skin Rash
- Statin Interactions with HIV or Hepatitis C Drugs Can Cause Muscle and Kidney Damage, FDA Warns
- Pharmasset Halts Testing of HCV Polymerase Inhibitor PSI-938 Due to Liver Problems
- PegIntron Label Updated to Include Use with New Direct-Acting HCV Agents
- FDA Updates Dosing of Pegasys plus Ribavirin for Hepatitis C Patients with Kidney Impairment
- Updated PegIntron Label Psychiatric Warning
Web Design and Development by